000181669 001__ 181669
000181669 005__ 20240229145653.0
000181669 0247_ $$2doi$$a10.1016/j.ejca.2022.08.015
000181669 0247_ $$2pmid$$apmid:36096040
000181669 0247_ $$2ISSN$$a0014-2964
000181669 0247_ $$2ISSN$$a0959-8049
000181669 0247_ $$2ISSN$$a1879-0852
000181669 0247_ $$2ISSN$$a(1990)
000181669 0247_ $$2ISSN$$a1879-2995
000181669 0247_ $$2ISSN$$a(1965)
000181669 0247_ $$2altmetric$$aaltmetric:135848715
000181669 037__ $$aDKFZ-2022-02153
000181669 041__ $$aEnglish
000181669 082__ $$a610
000181669 1001_ $$aHemminki, Janne$$b0
000181669 245__ $$aSurvival trends in solid cancers in the Nordic countries through 50 years.
000181669 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2022
000181669 3367_ $$2DRIVER$$aarticle
000181669 3367_ $$2DataCite$$aOutput Types/Journal article
000181669 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1663077101_16521
000181669 3367_ $$2BibTeX$$aARTICLE
000181669 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181669 3367_ $$00$$2EndNote$$aJournal Article
000181669 500__ $$a#LA:C020#
000181669 520__ $$aGlobal survival studies in cancer have generally shown favourable development, but studies over extended periods on populations for which medical care is essentially free of charge are lacking.We analyse relative 1- and 5-year survival in all solid cancers in Denmark, Finland, Norway and Sweden through a 50-year period (1970-2019) using the NORDCAN database.The most recent survival results showed three types of patterns. Cancers of very good survival (5-year survival ∼90%) included common cancers of the breast and prostate, as well as melanoma. The second pattern, which included the largest number of cancers, showed 1-year survival of over 80% and a drop of 10-20 % units in 5-year survival. The third group consisted of eight fatal cancers, sharing poor 5-year survival (around 20%). The 50-year improvement in 1-year survival was largest (30-50 % units) in kidney, brain, gallbladder and liver cancers, and (∼30%) in colon, small intestinal, lung, pleural, pancreas and ovarian cancers. Improvements in 5-year survival were highest (40-50 % units) in prostate and kidney cancers but remained at 10-20 % units for the eight fatal cancers. Survival showed significant sex preferences for a few cancers.The analysis over a half-century confirms the progress in 'real-world' cancer control, and in 84% of patients 5-year survival was >60%. Metastases remain a challenge, placing the emphasis on early detection before metastasis occurs. Novel therapies, such as immunotherapy which has curative potential even against metastatic disease, are needed.
000181669 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000181669 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181669 650_7 $$2Other$$aCancer control
000181669 650_7 $$2Other$$aPeriodic survival
000181669 650_7 $$2Other$$aPrognosis
000181669 650_7 $$2Other$$aTreatment
000181669 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000181669 7001_ $$0P:(DE-HGF)0$$aHemminki, Akseli$$b2
000181669 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b3$$eLast author$$udkfz
000181669 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2022.08.015$$gVol. 175, p. 77 - 85$$p77 - 85$$tEuropean journal of cancer$$v175$$x0014-2964$$y2022
000181669 909CO $$ooai:inrepo02.dkfz.de:181669$$pVDB
000181669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000181669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181669 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000181669 9141_ $$y2022
000181669 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000181669 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000181669 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000181669 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-30$$wger
000181669 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2021$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-30
000181669 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEUR J CANCER : 2021$$d2022-11-30
000181669 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000181669 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000181669 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000181669 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000181669 980__ $$ajournal
000181669 980__ $$aVDB
000181669 980__ $$aI:(DE-He78)B062-20160331
000181669 980__ $$aI:(DE-He78)HD01-20160331
000181669 980__ $$aI:(DE-He78)C020-20160331
000181669 980__ $$aUNRESTRICTED